Head-to-Head kidney cancer drug trial seeks better control
NCT ID NCT03541902
Summary
This study compares two existing drugs, cabozantinib and sunitinib, to see which is safer and more effective at controlling advanced kidney cancer that has spread. It is for patients with specific, less common types of kidney cancer. Participants are randomly assigned to take one of the two drugs by mouth daily, and doctors track how long the cancer is kept from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson Regional Care Center-Katy
Houston, Texas, 77094, United States
-
MD Anderson Regional Care Center-Sugar Land
Sugar Land, Texas, 77478, United States
Conditions
Explore the condition pages connected to this study.